IPO
-
-
-
-
-
-
-
UroGen Reports Fourth Quarter and Full Year 2017 Financial Results
-
-
-
-
-
-
-
UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder
-
-
-
-
-
-
-
UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
-
-
-
118,853 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

